August 20, 2012
Pfizer Inc. has decided to terminate the development of its investigational antibody drug bapineuzumab for the treatment of Alzheimer’s disease (AD), because the compound failed to meet the endpoints in multiple PIII studies. In an interview with Jiho, Inc. the...read more